GLP-1 Receptor Agonists Billing & Prior-Auth Playbook

What Are GLP-1 Receptor Agonists?

GLP-1 (glucagon-like peptide-1) receptor agonists are a drug class that mimics the incretin hormone GLP-1, which is secreted from intestinal L-cells after food intake. These agents bind and activate GLP-1 receptors in the pancreas, brain, gut, heart, and kidney. The result is glucose-dependent insulin secretion, suppressed glucagon, delayed gastric emptying, and reduced appetite signaling in the hypothalamus. FDA drug label summaries confirm these shared mechanisms across approved agents.

Approved Agents and Their Indications

Six GLP-1 receptor agonists currently hold FDA approval in the United States:

| Agent | Brand | Route | Primary Indication | |---|---|---|---| | Semaglutide | Ozempic / Wegovy / Rybelsus | SC weekly / oral daily | T2DM, obesity, CV risk | | Liraglutide | Victoza / Saxenda | SC daily | T2DM, obesity | | Dulaglutide | Trulicity | SC weekly | T2DM, CV risk | | Exenatide ER | Bydureon BCise | SC weekly | T2DM | | Exenatide | Byetta | SC twice daily | T2DM | | Tirzepatide | Mounjaro / Zepbound | SC weekly | T2DM, obesity |

Tirzepatide is technically a dual GIP/GLP-1 receptor agonist, but payers and most clinical guidelines group it within the GLP-1 class for formulary and prior-auth purposes. The FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023.

Mechanism Details That Matter for Medical Necessity Letters

Payers sometimes reject PA requests as "lifestyle drugs." A one-paragraph mechanism summary in your letter changes that framing. Semaglutide activates GLP-1 receptors in the arcuate nucleus, reducing neuropeptide Y signaling, a pathway that the ADA 2024 Standards of Care classifies as a pharmacological, not behavioral, intervention.

Clinical Efficacy Data You Need to Know by Agent

Citing specific trial data in a PA request or appeal letter significantly strengthens the medical necessity argument. Payer medical directors respond to named trials, not general statements.

Semaglutide: SUSTAIN, STEP, SELECT, and FLOW

The SUSTAIN-6 trial (N=3,297) showed subcutaneous semaglutide 0.5 mg and 1.0 mg weekly reduced major adverse cardiovascular events (MACE) by 26% vs. Placebo (HR 0.74, 95% CI 0.58 to 0.95) in patients with T2DM at high cardiovascular risk. SUSTAIN-6, NEJM 2016.

STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg weekly produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo (P<0.001). STEP-1, NEJM 2021. That single number, 14.9%, belongs in every Wegovy PA request.

SELECT (N=17,604) established a 20% reduction in MACE with semaglutide 2.4 mg in patients with obesity and established cardiovascular disease but without diabetes (HR 0.80, 95% CI 0.72 to 0.90). SELECT, NEJM 2023. This trial created the pathway for payers to cover Wegovy under cardiology benefits rather than pharmacy benefits.

The FLOW trial (N=3,533) found semaglutide 1.0 mg weekly reduced the composite kidney endpoint by 24% vs. Placebo in patients with T2DM and CKD (HR 0.76, 95% CI 0.66 to 0.88). FLOW, NEJM 2024. The FDA granted a new indication for CKD in May 2024, creating an additional billing pathway.

Tirzepatide: SURPASS and SURMOUNT

SURPASS-2 (N=1,879) showed tirzepatide 15 mg weekly reduced HbA1c by 2.46 percentage points vs. 1.86 points with semaglutide 1.0 mg at 40 weeks. SURPASS-2, NEJM 2021.

SURMOUNT-1 (N=2,539) demonstrated tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks vs. 2.4% placebo (P<0.001). SURMOUNT-1, NEJM 2022. No other approved single agent has matched that figure in a phase 3 RCT.

Liraglutide and Dulaglutide: Supporting Data

LEADER (N=9,340) showed liraglutide 1.8 mg daily reduced MACE by 13% vs. Placebo in high-CV-risk T2DM patients (HR 0.87, 95% CI 0.78 to 0.97). LEADER, NEJM 2016.

REWIND (N=9,901) showed dulaglutide 1.5 mg weekly reduced MACE by 12% vs. Placebo (HR 0.88, 95% CI 0.79 to 0.99), including patients with no prior CV event, a broader population than most other CV outcome trials. REWIND, The Lancet 2019.

Prior Authorization: How the Process Actually Works

PA for GLP-1 agents is standard practice across commercial, Medicare Part D, and Medicaid plans. Approval rates on first submission vary widely. Plans that require electronic PA (ePA) via CoverMyMeds or Surescripts process requests in 24 to 72 hours. Paper fax PA can take 5 to 14 business days.

What Every PA Request Must Include

Incomplete submissions are the leading cause of denial. Build a standard packet that includes the following:

• Diagnosis codes. Use E11.65 (T2DM with hyperglycemia) for Ozempic/Trulicity/Bydureon, E66.01 (morbid obesity due to excess calories) plus the patient's Z68.xx BMI code for Wegovy/Zepbound/Saxenda.
• Current HbA1c. Labs within 90 days. For T2DM agents, most plans require HbA1c >7.0%; some set the bar at >8.0%.
• Step-therapy documentation. For T2DM: documented trial of metformin and at least one additional oral agent (SGLT2i or DPP-4 inhibitor, depending on plan). For obesity agents: documented failure of behavioral intervention (typically 6 months) and sometimes a prior trial of phentermine/topiramate or orlistat.
• BMI measurement. For obesity indications: BMI >30 kg/m² or >27 kg/m² with at least one weight-related comorbidity (hypertension, T2DM, dyslipidemia, OSA). The SELECT trial population (BMI >27, established CVD) supports the lower threshold.
• Cardiovascular history. If the indication is CV risk reduction (Ozempic, Victoza, Trulicity), include documentation of prior MI, stroke, or established atherosclerotic cardiovascular disease (ASCVD).

Step-Therapy Requirements by Plan Type

Commercial plans vary considerably. Medicare Part D plans that cover Wegovy under the Inflation Reduction Act obesity benefit (effective 2026) have not yet published uniform step-therapy criteria. CMS guidance on obesity drug coverage for Medicare Part D is updated annually; confirm the current formulary year's criteria.

Medicaid coverage varies by state. As of 2024, fewer than 20 states cover anti-obesity medications including GLP-1 agents under Medicaid without specific legislative authorization. The Kaiser Family Foundation state drug coverage tracker documents current state-level status.

The HealthRX PA Triage Framework assigns each GLP-1 PA request to one of three tracks based on payer type and available documentation:

Track 1 (Expedited, <48 hours). Patient has T2DM, HbA1c >8.0%, documented metformin trial, and ASCVD history. Submit ePA with CV outcome trial citation (SUSTAIN-6, LEADER, or REWIND depending on agent). Approval rate in this track exceeds 75% at first submission.

Track 2 (Standard, 3 to 7 days). Obesity-only indication (BMI >30 or >27 with comorbidity), no prior GLP-1 use. Submit behavioral-intervention records, BMI trend over 12 months, and comorbidity documentation. Include SELECT trial abstract if CVD is present.

Track 3 (Appeals-first strategy). Patient has prior GLP-1 denial, Medicaid plan with no formulary coverage, or compound semaglutide request. Proceed directly to peer-to-peer review or external appeal. Do not resubmit the same packet.

Denial Reasons and How to Counter Each One

Knowing the denial language in advance lets you prepare the counterargument before the rejection arrives. These are the five most common denial categories for GLP-1 agents.

"Step Therapy Not Met"

This denial means the payer claims the patient has not tried required prior agents. Your response: submit pharmacy fill history (usually available from the PBM's own records), office notes documenting intolerance or contraindication, and, if the drug was truly never tried, a clinician letter explaining why it is contraindicated. Metformin is contraindicated in eGFR <30 mL/min/1.73m². KDIGO 2022 CKD guidelines confirm this threshold. Document the eGFR.

"Not Medically Necessary"

Counter with the mechanism paragraph (see above), the patient's specific HbA1c or BMI, the relevant RCT result (STEP-1 for Wegovy, SURMOUNT-1 for Zepbound, SUSTAIN-6 for Ozempic), and the applicable guideline recommendation. The ADA 2024 Standards of Care, Section 8 states: "For patients with type 2 diabetes who need greater glucose lowering than can be achieved with oral agents, GLP-1 receptor agonists are preferred over insulin due to lower hypoglycemia risk and weight benefit." Quote that sentence verbatim in the appeal letter.

"Obesity Is Not a Covered Benefit"

This is a contractual exclusion, not a clinical denial. Two options exist. First, check whether the agent can be billed under a different primary indication, if the patient has T2DM, Ozempic may be covered under the diabetes benefit even if obesity drugs are excluded. Second, invoke a cardiovascular indication: SELECT data supports Wegovy use in patients with BMI >27 and established CVD, reframing the indication from obesity to secondary CV prevention. SELECT trial, NEJM 2023.

"Quantity Limit Exceeded"

This typically arises when a patient is titrating and the prescriber wrote for 2 mg semaglutide before the plan recognizes the escalation schedule. Attach the FDA-approved titration schedule from the Wegovy prescribing information. FDA Wegovy label. Request a quantity limit exception, not a new PA.

"Drug Not on Formulary"

File a formulary exception request simultaneously with the PA. Formulary exceptions require evidence that all covered alternatives have been tried or are contraindicated. If tirzepatide is non-formulary but semaglutide is covered, and the patient has failed semaglutide, document the failure and request Zepbound as the medically necessary alternative. SURMOUNT-1 weight-loss data (22.5% vs. STEP-1's 14.9%) supports the superiority argument. SURMOUNT-1, NEJM 2022.

Billing Codes: Getting Reimbursed for the Visit

The PA process consumes clinical time that must be captured in billing.

Office Visit Coding

A new patient obesity and diabetes management visit with shared decision-making about GLP-1 initiation supports CPT 99205 (high medical decision making, new patient) or CPT 99215 (high MDM, established patient). Use modifier 25 when a separately identifiable service, such as a HbA1c review and medication adjustment, occurs on the same day as a preventive visit.

ICD-10 primary diagnosis codes to use:

• E11.65, T2DM with hyperglycemia (Ozempic, Victoza, Trulicity, Byetta, Bydureon)
• E11.9, T2DM without complication (acceptable but less specific)
• E66.01, Morbid (severe) obesity due to excess calories (Wegovy, Saxenda, Zepbound)
• Z68.41, Z68.45, BMI 40 to 59.9, used as secondary diagnosis code
• N18.3 / N18.4, CKD stage 3/4, for semaglutide CKD indication (FLOW-based approval)

Compounded Semaglutide: No Billing Pathway Exists

Compounded semaglutide and tirzepatide do not have NDC numbers. They cannot be billed through pharmacy benefits. Cash-pay pricing applies. The FDA has issued safety alerts regarding compounded semaglutide and has removed semaglutide from the drug shortage list, which means 503A and 503B compounders may no longer legally produce it under shortage authority. Prescribing compounded versions exposes the clinician to significant liability and offers patients no insurance recourse.

Medicare Part D Coverage Gaps

Under traditional Medicare Part D as of 2024, anti-obesity medications including Wegovy and Zepbound are excluded unless the patient has a covered comorbidity diagnosis. CMS Part D coverage policy classifies these as non-covered unless the plan specifically includes an obesity benefit. Beginning in 2026, the Inflation Reduction Act mandates limited obesity drug coverage in Part D, but final implementation rules are pending. Prescribers should document T2DM or ASCVD as the primary indication whenever clinically accurate to access the diabetes or cardiovascular benefit pathway now.

Peer-to-Peer Review: What to Say

Peer-to-peer (P2P) calls are the single most effective tool for reversing a GLP-1 denial. A 15-minute call with a payer medical director converts denials to approvals at a higher rate than written appeals alone.

Prepare Three Data Points Before the Call

1. The patient's specific HbA1c or BMI, plus the trajectory over the past 12 months.
2. The named RCT most relevant to the indication, with the primary endpoint result memorized.
3. The guideline sentence recommending GLP-1 use for this patient profile.

The Obesity Medicine Association 2023 Clinical Practice Guidelines state: "Anti-obesity pharmacotherapy should be considered for all patients with obesity (BMI >30 kg/m²) or overweight (BMI >27 kg/m²) with weight-related comorbidities who have not achieved adequate weight loss with lifestyle intervention alone." Read that sentence to the medical director. Ask whether the plan's step-therapy requirement is consistent with that guideline.

What Not to Say

Do not argue cost. Do not reference drug shortages. Do not mention that the patient has already been taking the drug. Focus exclusively on clinical indication, trial evidence, and guideline support. Payer medical directors respond to clinical logic, not logistical appeals.

Appeals: Building a Complete Administrative Record

If P2P fails, submit a first-level internal appeal within the plan's stated window (typically 30 to 60 days from denial). A complete appeal packet contains:

• The original denial letter (to identify the specific clinical rationale cited)
• A physician attestation letter (signed, dated, on letterhead)
• Relevant lab values with reference ranges
• Pharmacy fill history documenting prior agent trials
• A minimum of two primary literature citations (RCT level preferred)
• The applicable guideline excerpt with page number or section number

If the internal appeal fails, request an Independent Medical Review (IMR) or External Appeal, depending on state law. California, New York, and Texas have mandatory IMR processes. The ACA requires all non-grandfathered plans to offer external review.

External reviews overturn payer decisions in approximately 40 to 60% of cases for specialty medications when the clinical record is complete. The JAMA Internal Medicine 2023 analysis of external appeal outcomes found that patients who submitted supporting clinical documentation were significantly more likely to prevail.

Special Populations and Documentation Requirements

Patients with CKD

The FLOW trial created a new documentation pathway. For semaglutide in CKD, include: eGFR within 90 days, urine albumin-to-creatinine ratio (UACR), CKD stage (ICD-10 N18.3 or N18.4), and confirmation the patient is on a renin-angiotensin system (RAS) blocker as background therapy (FLOW required this at baseline). FLOW, NEJM 2024.

Pediatric Patients

The FDA approved liraglutide (Saxenda) for obesity in patients ages 12 and older in 2020. FDA approval, Saxenda pediatric. Semaglutide 2.4 mg (Wegovy) received pediatric approval (ages 12+) in December 2022. FDA approval, Wegovy pediatric. Pediatric PA packets require growth chart documentation, a dietitian note, and pediatric endocrinology or obesity medicine consultation in most plans.

Patients Transitioning from Compounded to Brand

When a patient has been on compounded semaglutide and the prescriber is transitioning to brand Wegovy, document the duration of compounded use, the dose achieved, and the clinical response (weight lost in kg, HbA1c change). Some plans will accept this as evidence of prior tolerance but not as step-therapy completion. Confirm with the plan before submitting.

Monitoring Requirements That Affect Continued Authorization

Most plans require re-authorization every 12 months. Continued-auth criteria typically include:

• Weight loss of at least 5% from baseline by month 4 (this is the clinical benchmark from STEP-1 responder analysis)
• Documented HbA1c improvement for T2DM indications
• No serious adverse events (pancreatitis, thyroid C-cell tumors in personal or family history of MEN2)

The Endocrine Society 2023 Obesity Pharmacotherapy Guideline recommends reassessing response at 12 to 16 weeks. If weight loss is <5% at 16 weeks on the maximum tolerated dose, the guideline supports discontinuation and switching agents, a clinical note documenting this decision protects against a continued-auth denial that cites inadequate response.

Thyroid C-cell tumor risk is a class-wide boxed warning. FDA GLP-1 class label warning, accessdata.fda.gov. Document that you screened for personal or family history of medullary thyroid carcinoma and MEN2 before initiating therapy. This note matters for liability and for responding to payer queries about appropriate patient selection.